Chimerix Inc (CMRX)
0.9043
-0.04
(-4.41%)
USD |
NASDAQ |
Nov 14, 16:00
0.9043
0.00 (0.00%)
After-Hours: 18:00
Chimerix Research and Development Expense (Quarterly): 18.43M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 18.43M |
| March 31, 2024 | 18.84M |
| December 31, 2023 | 15.64M |
| September 30, 2023 | 17.40M |
| June 30, 2023 | 16.93M |
| March 31, 2023 | 18.82M |
| December 31, 2022 | 19.28M |
| September 30, 2022 | 15.26M |
| June 30, 2022 | 18.05M |
| March 31, 2022 | 19.04M |
| December 31, 2021 | 34.34M |
| September 30, 2021 | 13.82M |
| June 30, 2021 | 13.80M |
| March 31, 2021 | 11.86M |
| December 31, 2020 | 8.687M |
| September 30, 2020 | 10.02M |
| June 30, 2020 | 8.578M |
| March 31, 2020 | 8.949M |
| December 31, 2019 | 7.493M |
| September 30, 2019 | 7.453M |
| June 30, 2019 | 13.83M |
| March 31, 2019 | 13.52M |
| December 31, 2018 | 15.28M |
| September 30, 2018 | 11.89M |
| June 30, 2018 | 13.71M |
| Date | Value |
|---|---|
| March 31, 2018 | 14.36M |
| December 31, 2017 | 12.91M |
| September 30, 2017 | 12.16M |
| June 30, 2017 | 11.64M |
| March 31, 2017 | 12.74M |
| December 31, 2016 | 11.70M |
| September 30, 2016 | 12.25M |
| June 30, 2016 | 13.76M |
| March 31, 2016 | 20.94M |
| December 31, 2015 | 31.85M |
| September 30, 2015 | 26.50M |
| June 30, 2015 | 21.86M |
| March 31, 2015 | 17.44M |
| December 31, 2014 | 15.67M |
| September 30, 2014 | 13.33M |
| June 30, 2014 | 8.092M |
| March 31, 2014 | 8.292M |
| December 31, 2013 | 6.283M |
| September 30, 2013 | 5.319M |
| June 30, 2013 | 6.276M |
| March 31, 2013 | 6.783M |
| December 31, 2012 | 6.283M |
| September 30, 2012 | 7.748M |
| June 30, 2012 | 9.082M |
| March 31, 2012 | 6.642M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.493M
Minimum
Dec 2019
34.34M
Maximum
Dec 2021
15.54M
Average
15.64M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 713.00M |
| Emergent BioSolutions Inc | 32.70M |
| SIGA Technologies Inc | -- |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| Geovax Labs Inc | 4.277M |